- | Clene Nanomedicine
One Fourth of Maryland’s Future 20 are Life Science Companies
Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinson’s disease, multiple sclerosis, and Amyotrophic Lateral Sclerosis. CNM-Au8 is part of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
- | Cerevance
Treating Cognitive Impairment in Patients with Schizophrenia
The drug in question, Cerevance, significantly improved cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trail, details the science behind the drug itself, and previews the next steps of his research.
- | Cue Biopharma
New Oncology Therapies Emerge Amidst COVID Pandemic
Cue Biopharma has managed to persevere through the COVID pandemic by employing a variety of strategies. President and Chief Scientific Officer, Anish Suri, and Ken Pienta, acting Chief Medical Officer discuss their experiences.
- | Chiasma
Chiasma set for EMA filing based on acromegaly data
Chiasma was trading 4% higher in the opening minutes on Wednesday.
- | Cerevance
Cerevance buoyed by postive clinical trial results for schizophrenia compound
Cambridge Science Park-based Cerevance has confirmed positive results from a trial of a potential treatment for cognitive impairment associated with schizophrenia.
- | INmune Bio
Blocking Neuroinflammation
Christopher J. Barnum, PhD, of INmune Bio, Inc discusses XPro1595, developed by INmune Bio, and how it may provide neuroprotective benefits for those at risk of developing Alzheimer disease.
- | OSE Immunotherapeutics
OSE details novel immuno-oncology strategy targeting ‘don’t eat me’ signaling in cancer
OSE Immunotherapeutics is among the companies pursuing this signaling pathway, and it has unveiled preclinical data supporting a novel strategy for disrupting it.
- | Heat Biologics
8 Biotech Startup Lessons From Heat Bio’s Jeff Wolf
Any time we have an opportunity to talk with Jeff Wolf, we take it – especially when the conversation tackles the highs and lows of leading a biotech startup. Currently the founder, chairman, and CEO at the clinical-stage immuno-oncology biopharma Heat Biologics (HTBX), Wolf previously founded or co-founded Avigen, Elusys, TyRx, Generation One, and Seed One Capital Ventures.
